VentriPoint Diagnostics (VPT) Investor update summary

Product and operating readiness

• VMS delivers cardiac volumetric measurements with accuracy comparable to MRI, works with ultrasound systems from any vendor, and is approved in the U.S., Europe and Canada; China approval is pending.

• VMS+ Version 4.0 commercialization includes customer upgrade readiness and clinical workflow planning; it received a 2026 Gold Edison Award in Precision Health Technologies.

• A Version 3.0 usability study reported 98% task completion, no critical errors and average workflow completion within 15 minutes; Version 4.0 has further workflow improvements.

• Training, installation and customer support processes are being standardized, with scalable materials and videos; manufacturing quality and regulatory audits were successful.

Commercial progress and outlook

• A subscription-based Device-as-a-Service model and expanded virtual and hospital demonstrations aim to reduce upfront barriers, shorten sales cycles and build recurring revenue.

• Year-end priorities are converting demonstrations and evaluations into subscriptions and placements, supporting V4.0 upgrades, and advancing partnership and regulatory milestones.

• Quarterly milestones included a Q1 unit sale, two U.S. system purchase commitments in Q2, a European evaluation shipment and unit sale in Q3, and a U.K. study launched in Q4.

• Innovate BC committed funding for the Providence Health Care Ventures collaboration, which forecasts placement of three systems and will establish a hub at St. Paul’s Hospital.

• The qualified pipeline includes ~6 leads or units awaiting installation and training; CRM is generating more than one qualified lead per week, with growth expected from Q1 2027.

Partnerships and market access

• VMS was selected for the AIRES study at Royal Wolverhampton NHS Trust, evaluating AI-enabled cardiac ultrasound in oncology patients receiving breast cancer chemotherapy.

• UniDoc discussions are advancing toward a formal arrangement for a hub-and-spoke model serving remote and underserved communities; the Providence collaboration is intended to scale regionally and beyond.

• The Ollie Hinkle Heart Foundation initiative supports pediatric cardiac imaging; its first system was manufactured, with final quality checks and shipment planned for the following week.

• VMS+ was submitted to China’s NMPA and qualifies for Green Channel review; Lishman’s investment is expected to follow Chinese approval, subject to its financing milestone.

• Ascend completed initial integration and is promoting VMS; a more advanced integration roadmap is ready to pursue when funding is available.